English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 912994      Online Users : 1144
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/6758


    Title: Neurocognitive effects of aripiprazole in adolescents and young adults with bipolar disorder
    Authors: Wang, LJ;Yeh, CB;Huang, YS;Tang, CS;Chou, WJ;Chou, MC;Chen, CK
    Contributors: Division of Mental Health and Addiction Medicine
    Abstract: Background: Patients with bipolar disorder have neurocognitive impairments, which are associated with poor functional outcomes. Aims: This study evaluated the neurocognitive effects of aripiprazole in adolescents and young adults with bipolar disorder. Methods: This was a 24-week, observational, prospective study performed in Taiwan. Participants in the study were clinically diagnosed as having bipolar disorder according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). In total, 28 patients participated and were administered aripiprazole. Neurocognitive function was assessed as a change from baseline in the Continuous Performance Test (CPT) and the Wisconsin Card Sorting Test (WCST). Results: The 28 patients had a mean age of 18.5 ± 3.3 years. During the 24-week aripiprazole treatment, these patients had significant improvements in omission score (χ(2) = 7.83, P = 0.050) and detectability scores (χ(2) = 13.79, P = 0.003) in the CPT, and perseverative errors (χ(2) = 17.42, P = 0.001) in the WCST. The WCST perseverative errors scores were significantly associated with general symptom scores in Brief Psychiatric Rating Scale (BPRS) (β = - 1.34, P = 0.024). No significant differences were found between the neurocognitive functions of patients with manic, depressive and mixed episodes from baseline to week 24. Conclusions: Adolescents and young adults with bipolar disorder experienced significant neurocognitive function improvements after treatment with aripiprazole. A randomized, controlled design is warranted to determine whether these improvements are associated with aripiprazole or the course of bipolar disorder
    Date: 2012-09
    Relation: Nordic Journal of Psychiatry. 2012 Sep;66(4):276-282.
    Link to: http://dx.doi.org/10.3109/08039488.2011.643484
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0803-9488&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000308413100008
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84865852168
    Appears in Collections:[其他] 期刊論文

    Files in This Item:

    File Description SizeFormat
    SCP84865852168.pdf88KbAdobe PDF427View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback